Viral Vector– tag –
-
VIVEbiotech Scales In Vivo Gene Therapy Portfolio to 15 Programs, Securing Key FDA Clinical Trial Approvals
PharmaSource スペイン Overview Spanish CDMO VIVEbiotech has significantly expanded its in vivo lentiviral vector gene therapy portfolio to 15 programs, several of which have already secured regulatory clearance for clinical trials, inclu... -
MDPI Paper Analyzes Direct Cellular Reprogramming Advances and Challenges: Functional Transformation of Fibrotic Tissues vs. Safety and Efficiency Bottlenecks
MDPI Switzerland Overview A scholarly article in MDPI reviews advances in direct cellular reprogramming for regenerative medicine, highlighting its potential to transform fibrotic tissues into functional parenchyma. However, it criticall... -
Non-Viral CRISPR/Cas9 HDR Platform Enables Stable Genetic Engineering of Solid Tumor Models, Overcoming Viral Vector Challenges
bioRxiv (Preprint) USA Overview This preprint reports research on a non-viral CRISPR/Cas9 Homology-Directed Repair (HDR) platform for stable genetic engineering of solid tumor models. This approach enables precise genome modification and... -
AGC Biologics & Asimov Revolutionize Viral Vector Manufacturing with Single-Plasmid Lentiviral Edge Packaging Cell Line License
MetaphysicalCells Unknown Overview AGC Biologics and Asimov have licensed Asimov's pre-engineered Lentiviral (LV) Edge Packaging cell line, poised to revolutionize viral vector manufacturing. AGC Biologics' Milan facility can now produce... -
Lonza Unveils Enhanced DNA-to-IND Biologics Manufacturing Offering with 6-Month Timelines, Introducing GS Ori-Go™
PharmaSource Switzerland Overview Lonza has announced an enhanced 'DNA-to-IND' offering for biologics, aiming to achieve IND-readiness for monoclonal antibody programs in as little as six months. This accelerated timeline is supported by... -
Fujifilm Diosynth Biotechnologies Strengthens Technological Leadership in Cell Culture, Microbial Fermentation, Viral Vectors, and Cell Therapy Manufacturing
MabDesign France Overview Fujifilm Diosynth Biotechnologies is focused on combining its technological leadership with cGMP manufacturing facilities across key areas: cell culture, microbial fermentation, viral vectors, and cell therapy. ... -
Neuron Reports Novel Small Molecule Temporarily Opens Blood-Brain Barrier, Significantly Enhancing CNS Drug Delivery Preclinically
Neuron USA Overview A research paper in Neuron presented compelling preclinical data for a novel small molecule designed to temporarily and reversibly open the blood-brain barrier (BBB). This groundbreaking technology holds the potential... -
Novel AAV Capsid Designs for Gene Therapy Highlighted at ASGCT 2026, Improving Tissue Tropism and Immunogenicity
Gene Therapy News USA Overview The American Society of Gene and Cell Therapy (ASGCT) 2026 annual meeting highlighted several presentations on innovative adeno-associated virus (AAV) capsid designs. These new designs aim to enhance the ov... -
FDA Grants Fast Track Designation to Investigational Gene Therapy for Rare Inherited Eye Disease
FDA Press Release USA Overview The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to an investigational gene therapy for a serious rare inherited eye disease. This designation aims to facilitate development an... -
Voyager Therapeutics Receives FDA IND Clearance for VY1706, First Tau-Targeted Gene Therapy, to Begin Alzheimer’s Disease Phase 1 Trial
Cell & Gene Therapy Review USA Overview Voyager Therapeutics announced that its Investigational New Drug (IND) application for VY1706, a tau-targeted gene therapy for Alzheimer's disease, has been cleared by the FDA. VY1706 is a potent a...
